{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:17:15Z","timestamp":1761999435071,"version":"build-2065373602"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.7759\/cureus.95890","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:14:31Z","timestamp":1761999271000},"source":"Crossref","is-referenced-by-count":0,"title":["Schizophrenia: What We Know and What We Are Yet to Know"],"prefix":"10.7759","author":[{"given":"David","family":"Chinonyerem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Promise T","family":"Awe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisom O","family":"Okaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20020147","article-title":"On the origins of schizophrenia","volume":"177","author":"Kahn RS","year":"2020","unstructured":"Kahn RS. On the origins of schizophrenia. Am J Psychiatry. 2020, 177:291-7. 10.1176\/appi.ajp.2020.20020147","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.11.015","article-title":"The schizophrenia syndrome, circa 2024: what we know and how that informs its nature","volume":"264","author":"Tandon R","year":"2024","unstructured":"Tandon R, Nasrallah H, Akbarian S, et al.. The schizophrenia syndrome, circa 2024: what we know and how that informs its nature. Schizophr Res. 2024, 264:1-28. 10.1016\/j.schres.2023.11.015","journal-title":"Schizophr Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1015616","article-title":"Unrecognized schizophrenia spectrum and other mental disorders in youth disconnected from education and work-life","volume":"13","author":"Lindhardt L","year":"2022","unstructured":"Lindhardt L, Nilsson LS, Munk-J\u00f8rgensen P, Mortensen OS, Simonsen E, Nordgaard J. Unrecognized schizophrenia spectrum and other mental disorders in youth disconnected from education and work-life. Front Psychiatry. 2022, 13:1015616. 10.3389\/fpsyt.2022.1015616","journal-title":"Front Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1529100617727266","article-title":"Three approaches to understanding and classifying mental disorder: ICD-11, DSM-5, and the National Institute of Mental Health's Research Domain Criteria (RDoC)","volume":"18","author":"Clark LA","year":"2017","unstructured":"Clark LA, Cuthbert B, Lewis-Fern\u00e1ndez R, Narrow WE, Reed GM. Three approaches to understanding and classifying mental disorder: ICD-11, DSM-5, and the National Institute of Mental Health's Research Domain Criteria (RDoC). Psychol Sci Public Interest. 2017, 18:72-145. 10.1177\/1529100617727266","journal-title":"Psychol Sci Public Interest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02175-z","article-title":"Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders","volume":"28","author":"Boyer L","year":"2023","unstructured":"Boyer L, Falissard B, Nuss P, et al.. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023, 28:3709-16. 10.1038\/s41380-023-02175-z","journal-title":"Mol Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01426-x","article-title":"Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes","volume":"48","author":"Howes OD","year":"2023","unstructured":"Howes OD, Cummings C, Chapman GE, Shatalina E. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. Neuropsychopharmacology. 2023, 48:151-67. 10.1038\/s41386-022-01426-x","journal-title":"Neuropsychopharmacology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2009.12.003","article-title":"The role of genetics in the etiology of schizophrenia","volume":"33","author":"Gejman PV","year":"2010","unstructured":"Gejman PV, Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am. 2010, 33:35-66. 10.1016\/j.psc.2009.12.003","journal-title":"Psychiatr Clin North Am"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.10.015","article-title":"Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia","volume":"69","author":"Strauss GP","year":"2011","unstructured":"Strauss GP, Frank MJ, Waltz JA, Kasanova Z, Herbener ES, Gold JM. Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol Psychiatry. 2011, 69:424-31. 10.1016\/j.biopsych.2010.10.015","journal-title":"Biol Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu006","article-title":"Schizophrenia--time to commit to policy change","volume":"40 Suppl 3","author":"Fleischhacker WW","year":"2014","unstructured":"Fleischhacker WW, Arango C, Arteel P, et al.. Schizophrenia--time to commit to policy change. Schizophr Bull. 2014, 40 Suppl 3:S165-94. 10.1093\/schbul\/sbu006","journal-title":"Schizophr Bull"},{"key":"ref10","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel KR","year":"2014","unstructured":"Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014, 39:638-45.","journal-title":"P T"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-5. American Psychiatric Publishing, Inc., Washington, DC; 2013. 10.1176\/appi.books.9780890425596"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpsm.2020.01.001","article-title":"Schizophrenia in ICD-11: comparison of ICD-10 and DSM-5","volume":"13","author":"Valle R","year":"2020","unstructured":"Valle R. Schizophrenia in ICD-11: comparison of ICD-10 and DSM-5. Rev Psiquiatr Salud Ment (Engl Ed). 2020, 13:95-104. 10.1016\/j.rpsm.2020.01.001","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2010.12.3\/ajablensky","article-title":"The diagnostic concept of schizophrenia: its history, evolution, and future prospects","volume":"12","author":"Jablensky A","year":"2010","unstructured":"Jablensky A. The diagnostic concept of schizophrenia: its history, evolution, and future prospects. Dialogues Clin Neurosci. 2010, 12:271-87. 10.31887\/DCNS.2010.12.3\/ajablensky","journal-title":"Dialogues Clin Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01330-w","article-title":"Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank","volume":"11","author":"Wainberg M","year":"2021","unstructured":"Wainberg M, Jacobs GR, di Forti M, Tripathy SJ. Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. Transl Psychiatry. 2021, 11:211. 10.1038\/s41398-021-01330-w","journal-title":"Transl Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20611","article-title":"Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders","volume":"18","author":"Reed GM","year":"2019","unstructured":"Reed GM, First MB, Kogan CS, et al.. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry. 2019, 18:3-19. 10.1002\/wps.20611","journal-title":"World Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.17816\/CP62","article-title":"The evolution of approaches to schizophrenia diagnostics: from Kraepelin to ICD-11","volume":"2","author":"Shmukler AB","year":"2021","unstructured":"Shmukler AB. The evolution of approaches to schizophrenia diagnostics: from Kraepelin to ICD-11. Consort Psychiatr. 2021, 2:65-70. 10.17816\/CP62","journal-title":"Consort Psychiatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon RA","year":"2023","unstructured":"McCutcheon RA, Keefe RS, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023, 28:1902-18. 10.1038\/s41380-023-01949-9","journal-title":"Mol Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S455279","article-title":"New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists","volume":"20","author":"Peng A","year":"2024","unstructured":"Peng A, Chai J, Wu H, Bai B, Yang H, He W, Zhao Y. New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists. Neuropsychiatr Dis Treat. 2024, 20:607-20. 10.2147\/NDT.S455279","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291714000774","article-title":"Cognitive variability in psychotic disorders: a cross-diagnostic cluster analysis","volume":"44","author":"Lewandowski KE","year":"2014","unstructured":"Lewandowski KE, Sperry SH, Cohen BM, Ong\u00fcr D. Cognitive variability in psychotic disorders: a cross-diagnostic cluster analysis. Psychol Med. 2014, 44:3239-48. 10.1017\/S0033291714000774","journal-title":"Psychol Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.05.027","article-title":"Striatal and extrastriatal dopamine D2\/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography","volume":"68","author":"Kegeles LS","year":"2010","unstructured":"Kegeles LS, Slifstein M, Xu X, et al.. Striatal and extrastriatal dopamine D2\/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry. 2010, 68:634-41. 10.1016\/j.biopsych.2010.05.027","journal-title":"Biol Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin SG","year":"2020","unstructured":"Potkin SG, Kane JM, Correll CU, et al.. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020, 6:1. 10.1038\/s41537-019-0090-z","journal-title":"NPJ Schizophr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon RA","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019, 42:205-20. 10.1016\/j.tins.2018.12.004","journal-title":"Trends Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00904-0","article-title":"Schizophrenia: from neurochemistry to circuits, symptoms and treatments","volume":"20","author":"Howes OD","year":"2024","unstructured":"Howes OD, Bukala BR, Beck K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nat Rev Neurol. 2024, 20:22-35. 10.1038\/s41582-023-00904-0","journal-title":"Nat Rev Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2021.11.001","article-title":"Assessing striatal dopamine in schizophrenia","volume":"91","author":"Tamminga CA","year":"2022","unstructured":"Tamminga CA. Assessing striatal dopamine in schizophrenia. Biol Psychiatry. 2022, 91:170-2. 10.1016\/j.biopsych.2021.11.001","journal-title":"Biol Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054160","article-title":"Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study","volume":"11","author":"Millgate E","year":"2021","unstructured":"Millgate E, Kravariti E, Egerton A, et al.. Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. BMJ Open. 2021, 11:e054160. 10.1136\/bmjopen-2021-054160","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.880568","article-title":"Immune system abnormalities in schizophrenia: an integrative view and translational perspectives","volume":"13","author":"Ermakov EA","year":"2022","unstructured":"Ermakov EA, Melamud MM, Buneva VN, Ivanova SA. Immune system abnormalities in schizophrenia: an integrative view and translational perspectives. Front Psychiatry. 2022, 13:880568. 10.3389\/fpsyt.2022.880568","journal-title":"Front Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112890","article-title":"DNA methylation and schizophrenia: current literature and future perspective","volume":"10","author":"Magwai T","year":"2021","unstructured":"Magwai T, Shangase KB, Oginga FO, Chiliza B, Mpofana T, Xulu KR. DNA methylation and schizophrenia: current literature and future perspective. Cells. 2021, 10:2890. 10.3390\/cells10112890","journal-title":"Cells"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000495063","article-title":"Epigenetic factors in schizophrenia: mechanisms and experimental approaches","volume":"5","author":"F\u00f6cking M","year":"2019","unstructured":"F\u00f6cking M, Doyle B, Munawar N, Dillon ET, Cotter D, Cagney G. Epigenetic factors in schizophrenia: mechanisms and experimental approaches. Mol Neuropsychiatry. 2019, 5:6-12. 10.1159\/000495063","journal-title":"Mol Neuropsychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4181","article-title":"Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex","volume":"19","author":"Jaffe AE","year":"2016","unstructured":"Jaffe AE, Gao Y, Deep-Soboslay A, Tao R, Hyde TM, Weinberger DR, Kleinman JE. Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex. Nat Neurosci. 2016, 19:40-7. 10.1038\/nn.4181","journal-title":"Nat Neurosci"},{"key":"ref30","unstructured":"What genes are differentially expressed in individuals with schizophrenia?. (2024). Accessed. August 21, 2025: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42020132433."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy V","year":"2022","unstructured":"Trubetskoy V, Pardi\u00f1as AF, Qi T, et al.. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022, 604:502-8. 10.1038\/s41586-022-04434-5","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae044","article-title":"Shared genetic determinants of schizophrenia and autism spectrum disorder implicate opposite risk patterns: a genome-wide analysis of common variants","volume":"50","author":"Chen Y","year":"2024","unstructured":"Chen Y, Li W, Lv L, Yue W. Shared genetic determinants of schizophrenia and autism spectrum disorder implicate opposite risk patterns: a genome-wide analysis of common variants. Schizophr Bull. 2024, 50:1382-95. 10.1093\/schbul\/sbae044","journal-title":"Schizophr Bull"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-2236(00)01862-2","article-title":"Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse","volume":"24","author":"Mirnics K","year":"2001","unstructured":"Mirnics K, Middleton FA, Lewis DA, Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 2001, 24:479-86. 10.1016\/s0166-2236(00)01862-2","journal-title":"Trends Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2017.00322","article-title":"Genetics of schizophrenia: overview of methods, findings and limitations","volume":"11","author":"Henriksen MG","year":"2017","unstructured":"Henriksen MG, Nordgaard J, Jansson LB. Genetics of schizophrenia: overview of methods, findings and limitations. Front Hum Neurosci. 2017, 11:322. 10.3389\/fnhum.2017.00322","journal-title":"Front Hum Neurosci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2010.07.019","article-title":"Ethnicity and symptom expression in patients with acute schizophrenia","volume":"185","author":"Chang N","year":"2011","unstructured":"Chang N, Newman J, D'Antonio E, McKelvey J, Serper M. Ethnicity and symptom expression in patients with acute schizophrenia. Psychiatry Res. 2011, 185:453-5. 10.1016\/j.psychres.2010.07.019","journal-title":"Psychiatry Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/s0920-9964(02)00223-2","article-title":"A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders","volume":"60","author":"Barrio C","year":"2003","unstructured":"Barrio C, Yamada AM, Atuel H, Hough RL, Yee S, Berthot B, Russo PA. A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. Schizophr Res. 2003, 60:259-69. 10.1016\/s0920-9964(02)00223-2","journal-title":"Schizophr Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/412143-schizophrenia-what-we-know-and-what-we-are-yet-to-know","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:14:31Z","timestamp":1761999271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/412143-schizophrenia-what-we-know-and-what-we-are-yet-to-know"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.95890","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}